ArticleACS medicinal chemistry letters2019
Second-Generation Tryptamine Derivatives Potently Sensitize Colistin Resistant Bacteria to Colistin.
Article in ACS medicinal chemistry letters, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 15 citations in OpenAlex.
- Cytotoxicity and Nanoassembly Characteristics of Aromatic Amides of Oleanolic Acid and Ursolic Acid.ACS omega · 2025Article
- Polymyxins induce lipid scrambling and disrupt the homeostasis of Gram-negative bacteria membrane.Biophysical journal · 2022Article
- Article
- Benzimidazole Isosteres of Salicylanilides Are Highly Active Colistin Adjuvants.ACS infectious diseases · 2021Article
- Novel Oleanolic Acid-Tryptamine and -Fluorotryptamine Amides: From Adaptogens to Agents Targeting In Vitro Cell Apoptosis.Plants (Basel, Switzerland) · 2021Article
- Augmenting the Activity of Macrolide Adjuvants againstACS medicinal chemistry letters · 2020Article
- Structure-Function Studies on IMD-0354 Identifies Highly Active Colistin Adjuvants.ChemMedChem · 2020Article
- Polymyxin B Loosens Lipopolysaccharide Bilayer but Stiffens Phospholipid Bilayer.Biophysical journal · 2020Article
- Article
- Repurposing Eukaryotic Kinase Inhibitors as Colistin Adjuvants in Gram-Negative Bacteria.ACS infectious diseases · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
Antibiotic resistance has significantly increased since the beginning of the 21st century. Currently, the polymyxin colistin is typically viewed as the antibiotic of last resort for the treatment of multidrug resistant Gram-negative bacterial infections. However, increased colistin usage has resulted in colistin-resistant bacterial isolates becoming more common. The recent dissemination of plasmid-borne colistin resistance genes (
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.